[Treatment of S-1 plus weekly CDDP for advanced gastric cancer].

Takeshi Kemmochi, Tomohisa Egawa, Yasunori Mihara, Tomoyuki Irino, Yasuhiro Ito, Atsushi Nagashima, Hiroyuki Makino, Wataru Yamamuro

Research output: Contribution to journalArticlepeer-review


We analyzed the clinical efficacy and safety of chemotherapy using S-1 plus weekly CDDP( w-CS therapy) for unresectable gastric cancer. Twenty one patients were treated with this treatment. S-1 80 mg/m2/day was administered for 2 weeks followed by a 1-week rest. CDDP 20 mg/m2 was injected intravenously on day 1 and 8. The overall response rate was 52. 3%. The disease control rate was 85.7%. Grade 3 or 4 major toxicity comprised neutropenia (14.2%), thrombocytopenia (4.7%) and plasma creatinine elevation (4.7%). w-CS therapy is satisfied resulting with efficacy and safety. Thus, future clinical trials and accumulation of futher cases are warranted.

Original languageEnglish
Pages (from-to)2351-2353
Number of pages3
JournalGan to kagaku ryoho. Cancer & chemotherapy
Issue number12
Publication statusPublished - 2011 Nov
Externally publishedYes

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of '[Treatment of S-1 plus weekly CDDP for advanced gastric cancer].'. Together they form a unique fingerprint.

Cite this